2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179473
    MK-0626 690257-74-0
    MK-0626 is a selective, orally active DPP-4 inhibitor with an IC50 of 6.3 nM. MK-0626 increases endothelial nitric oxide synthetase expression. MK-0626 improves neovascularization, attenuates hepatic steatosis, attenuates pancreatic islet injury. MK-0626 can be used in the research of diabetes and non-alcoholic fatty liver disease.
    MK-0626
  • HY-179595
    GSK4394835A 3032458-06-0
    GSK4394835A is a reversible covalent inhibitor of PDE3B with a pIC50 of 6.2. GSK4394835A can be used for cardiovascular disease research.
    GSK4394835A
  • HY-179636
    DS-1040 Tosylate prodrug-1 1335138-79-8 98%
    DS-1040 Tosylate prodrug-1 (Compound 2) is a prodrug of DS-1040 Tosylate (Compound 1) (HY-101918). DS-1040 Tosylate prodrug-1 can be used to study thromboembolic diseases.
    DS-1040 Tosylate prodrug-1
  • HY-179687
    JAK2-IN-18 3108318-77-7
    JAK2-IN-18 (Compound example1) is a selective JAK2 inhibitor. JAK2-IN-18 can inhibit JAK-STAT signaling and shows an IC50 of <100 nM for pSTAT5 in HEL9217 cells. JAK2-IN-18 can inhibit the proliferation of abnormally proliferating myeloid cells and can be used for the research of myeloproliferative disorders, such as essential thrombocythemia.
    JAK2-IN-18
  • HY-179707
    GRL-03022
    GRL-03022 is a potent, selective and non-covalent G protein-coupled receptor kinase 5 (GRK5) inhibitor with an IC50 of 60 nM. GRL-03022 exhibits >16000-fold selectivity over GRK2 (IC50 > 1000 μM). GRL-03022 can be used for heart failure and cancer research.
    GRL-03022
  • HY-180109
    Benzo-17R-RvD2 98%
    Benzo-17R-RvD2 (Benzo-17R-Resolvin D2) is a benzo-containing analog of RvD2 (HY-121636). Benzo-17R-RvD2 enhances human macrophage efferocytosis, limits neutrophil infiltration, reduces TNF-α, and increases IL-1 receptor antagonist in peritonitis. Benzo-17R-RvD2 promotes E. coli killing by human leukocytes and reduces neutrophil swarm area without compromising anti-Candida activity. Benzo-17R-RvD2 activates the human-RvD2 receptor with an EC50 ∼1.5 nM. Benzo-17R-RvD2 can be used in research on inflammation-associated diseases such as cardiovascular disease, cancer, neuroinflammation, pain, and muscle regeneration.
    Benzo-17R-RvD2
  • HY-180164
    DS79540454 1462947-17-6 98%
    DS79540454 is a HIF-PHD2 inhibitor with an IC50 0.26 μM. DS79540454 can be used in the research of renal anemia.
    DS79540454
  • HY-180165
    Antiallergic agent-5
    Antiallergic agent-5 (Compound 4f) is an antiallergic agent. Antiallergic agent-5 suppresses Ca2+ influx. Antiallergic agent-5 suppresses IgE/Ag-induced release of both IL-6 and TNF-α. Antiallergic agent-5 inhibits mast cell degranulation. Antiallergic agent-5 attenuates passive cutaneous anaphylaxis in mice and reduces vascular leakage.
    Antiallergic agent-5
  • HY-180188
    F1-ispinesib
    F1-ispinesib is a heterobifunctional F1-autophagy degrader, composed of an RNA-binding fragment (F1) and the LC3B ligand Ispinesib (HY-50759). F1-ispinesib induces degradation of COL15A1 mRNA via an LC3B-dependent macroautophagy mechanism. F1-ispinesib inhibits cell proliferation and enhances migration of human aortic smooth muscle cells.
    F1-ispinesib
  • HY-180194
    SERCA2a activator 2
    SERCA2a activator 2 (Compound 25) is a potent SERCA2a (cardiac type) activator, which also has an activating effect on SERCA1a (skeletal muscle type). SERCA2a activator 2, under [Ca²⁺]MAX conditions activates the ATPase activity of SERCA2a and promotes Ca²⁺ uptake, with its EC₅₀ values being 4 μM and 0.80 μM respectively. SERCA2a activator 2 also exhibits consistent activating effects under more physiological [Ca²⁺]MID conditions. SERCA2a activator 2 has low cytotoxicity and can be used for research on diseases such as heart failure.
    SERCA2a activator 2
  • HY-180197
    PICK1 PDZ-IN-1
    PICK1 PDZ-IN-1 (Compound 6b) is a selective and brain-penetrant protein interacting with C kinase 1 (PICK1) PDZ domain inhibitor with a Ki of 27.73 μM. PICK1 PDZ-IN-1 can competitively inhibit the interaction between PICK1 and the GluA2 subunit of AMPA receptors. PICK1 PDZ-IN-1 can increase the survival rate of HT22 cells and primary cortical neuron cells induced by glutamate and inhibit ROS production. PICK1 PDZ-IN-1 exhibits neuroprotective effect and reduces the area of cerebral infarction. PICK1 PDZ-IN-1 can be used for the research of ischemic stroke.
    PICK1 PDZ-IN-1
  • HY-180214
    HDAC6-IN-69 98%
    HDAC6-IN-69 is a brain-penetrant and highly selective HDAC6 inhibitor with an IC50 of 4.0 nM. HDAC6-IN-69 shows >176-fold against other HDAC isoforms. HDAC6-IN-69 engages the target in neuronal cells by dose-dependently upregulating acetylated α-tubulin in virto. HDAC6-IN-69 has neuroprotective effect and can be used for ischemic stroke research .
    HDAC6-IN-69
  • HY-180224
    HDAC6-IN-70
    HDAC6-IN-70 (Compound 9q) is a selective HDAC6 inhibitor with an IC50 of 29 nM. HDAC6-IN-70 effectively inhibits tubulin polymerization and HDAC6. HDAC6-IN-70 causes Apoptosis. HDAC6-IN-70 shows anticancer effects on hematological malignancies and colorectal cancers.
    HDAC6-IN-70
  • HY-180267
    (R)-Chloro-butylphthalide-O-NBP
    (R)-Chloro-butylphthalide-O-NBP, a chiral 3-n-butylphthalide derivative, is a neuroprotective agent. (R)-Chloro-butylphthalide-O-NBP shows potent blood-brain barrier (BBB) protective function. In vivo, (R)-Chloro-butylphthalide-O-NBP significantly reduces infarct volume and markedly preserves BBB integrity. (R)-Chloro-butylphthalide-O-NBP can be used for the research of ischemic stroke.
    (R)-Chloro-butylphthalide-O-NBP
  • HY-180322
    TG2-IN-3h 1592640-75-9
    TG2-IN-3h (Compound 3h) is a transglutaminase (TG2) inhibitor (hTG2: IC50 = 6nM). TG2-IN-3h inhibits endothelial cell migration and angiogenesis. TG2-IN-3h alleviates renal fibrosis in a mouse model of hypertensive nephropathy. TG2-IN-3h can be used in research on metabolic diseases such as hypertensive nephropathy and cardiovascular and cerebrovascular diseases such as pathological angiogenesis.
    TG2-IN-3h
  • HY-180334
    S-312 120004-07-1
    S-312 is a calcium antagonist with a bicyclic dihydrothienopyridine structure. S-312 can relax the helical strips of various isolated rabbit arteries procontracted with high potassium depolarizaiton. S-312 competitively imhibits calcium-induced contractions in depolarized basilar and femoral arteries. S-312 increases AV nodal conduction time in Langenedorff-perfused isolated rabbit hearts. S-312 exhibits vasculoselectivity, particularly for cerebral vessel.
    S-312
  • HY-180335
    L 691121 free base 136075-61-1
    L 691121 (free base) is the major metabolite of L 691121 in plasma. L 691121 (free base) is a class IIIantiarrhythmic agent that blocks potassium currents.
    L 691121 free base
  • HY-180344
    Flurpiridaz 863888-33-9
    Flurpiridaz is a positron emission tomography (PET) myocardial perfusion imaging tracer. Flurpiridaz can bind to mitochondrial complex I with high affinity. Flurpiridaz demonstrates high heart uptake in multiple species with clear delineation of perfusion deficits. Flurpiridaz shows rapid uptake in the myocardium. Flurpiridaz can be studied in research on coronary artery disease.
    Flurpiridaz
  • HY-180354
    Mopidralazine hydrochloride 86703-02-8 98%
    Mopidralazine hydrochloride (MDL-899) (Compound 30) is an orally active antihypertensive agent. Mopidralazine hydrochloride significantly reduces systolic blood pressure (ED50 = 1.94 mg/kg) in spontaneously hypertensive rats models. Mopidralazine hydrochloride has a slower onset of action but a longer duration of action and has a significantly smaller effect on increasing heart rate in canine model of renal hypertension. Mopidralazine hydrochloride can be used for the research of hypertension.
    Mopidralazine hydrochloride
  • HY-180370
    Nitromemantine 765890-91-3 98%
    Nitromemantine (NitroSynapsin) is a nitrate derivative of Memantine (HY-B0591) and is a dual-functional NMDAR antagonist. Nitromemantine exhibits significant efficacy in rodent models of cerebral infarction through a dual mechanism of blocking channels and regulating receptors via NO/redox regulation. Nitromemantine can target ischemic neurons under hypoxic conditions and enhance its activity. Nitromemantine inhibits the current induced by NMDA, with its IC50 being 2.4 μM. Nitromemantine can be used for the study of cerebral ischemic stroke.
    Nitromemantine
Cat. No. Product Name / Synonyms Application Reactivity